UPDATED May 02, 2024
All the companies in the healthcare sector, including healthcare provider and equipment, healthcare tech, pharmaceuticals, biotech and life sciences.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
LLY | US$734.97 | 0.2% | 71.8% | US$680.6b | US$848.35 | PE107.8x | E27.0% | 0.7% | Pharmaceuticals & Biotech | ||
UNH | US$492.45 | -0.6% | -0.4% | US$453.6b | US$567.36 | PE29.5x | E19.5% | 1.5% | Healthcare | ||
JNJ | US$149.27 | 2.1% | -8.2% | US$360.8b | US$173.26 | PE21x | E7.0% | 3.3% | Pharmaceuticals & Biotech | ||
MRK | US$127.51 | -2.8% | 8.4% | US$324.9b | US$141.64 | PE140.1x | E24.9% | 2.4% | Pharmaceuticals & Biotech | ||
ABBV | US$163.79 | 2.6% | 10.6% | US$284.7b | US$182.31 | PE48.7x | E23.3% | 3.8% | Pharmaceuticals & Biotech | ||
AZN | UK£121.56 | 1.4% | 2.0% | UK£188.4b | UK£131.66 | PE37.4x | E16.5% | 2.0% | Pharmaceuticals & Biotech | ||
TMO | US$571.25 | -0.08% | 4.7% | US$219.5b | US$625.47 | PE36.1x | E10.6% | 0.3% | Pharmaceuticals & Biotech | ||
ABT | US$105.90 | -1.5% | -4.8% | US$183.8b | US$126.09 | PE32.8x | E11.3% | 2.1% | Healthcare | ||
DHR | US$248.38 | 0.7% | 2.5% | US$182.8b | US$272.68 | PE45.2x | E13.5% | 0.4% | Pharmaceuticals & Biotech | ||
PFE | US$27.70 | 9.7% | -27.5% | US$153.9b | US$31.89 | PE73.5x | E22.0% | 6.1% | Pharmaceuticals & Biotech | ||
AMGN | US$278.39 | 3.3% | 20.1% | US$148.8b | US$298.30 | PE22.2x | E9.1% | 3.2% | Pharmaceuticals & Biotech | ||
ISRG | US$381.36 | 1.6% | 25.1% | US$134.0b | US$420.38 | PE68.1x | E11.6% | n/a | Healthcare | ||
SYK | US$326.63 | -3.1% | 14.8% | US$124.8b | US$372.35 | PE37x | E10.5% | 1.0% | Healthcare | ||
ELV | US$526.96 | -1.9% | 13.5% | US$122.2b | US$603.15 | PE19.6x | E12.4% | 1.2% | Healthcare | ||
MDT | US$81.69 | 2.4% | -9.3% | US$107.4b | US$94.77 | PE25.8x | E9.7% | 3.4% | Healthcare | ||
BSX | US$72.85 | -0.4% | 41.3% | US$105.9b | US$81.00 | PE60.7x | E18.1% | n/a | Healthcare | ||
VRTX | US$401.08 | 0.9% | 15.2% | US$103.4b | US$460.23 | PE28.6x | E11.4% | n/a | Pharmaceuticals & Biotech | ||
REGN | US$957.00 | 8.4% | 25.6% | US$101.2b | US$1,033.38 | PE26.8x | E12.1% | n/a | Pharmaceuticals & Biotech | ||
CI | US$341.50 | -3.7% | 31.0% | US$97.7b | US$388.64 | PE26.8x | E18.6% | 1.6% | Healthcare | ||
BMY | US$43.70 | -2.2% | -34.6% | US$89.6b | US$53.32 | PS1.9x | E43.1% | 5.5% | Pharmaceuticals & Biotech | ||
GSK | UK£17.29 | 4.6% | 18.2% | UK£70.5b | UK£20.20 | PE15.7x | E11.9% | 3.4% | Pharmaceuticals & Biotech | ||
CSL | AU$275.80 | 0.9% | -8.4% | AU$133.3b | AU$306.40 | PE35.5x | E14.7% | 1.3% | Pharmaceuticals & Biotech | ||
GILD | US$65.33 | 0.09% | -16.8% | US$81.7b | US$83.46 | PE168x | E36.7% | 4.7% | Pharmaceuticals & Biotech | ||
HCA | US$307.76 | 0.3% | 10.7% | US$81.7b | US$344.35 | PE14.9x | E6.0% | 0.9% | Healthcare |